Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has added a new report providing an overview of the different types of risk-sharing agreements adopted by manufacturers.
“Pricing and Reimbursement:
The report further shows that risk-sharing schemes are ideal if a well-established biomarker unmistakably determines if a patient has responded to treatment. However for many other oncology drugs, relevant biomarkers still need to be discovered, for this reason impeding a more widespread adoption of these schemes.
Autors of the report note that the new ‘National Institute for Health and Clinical Evidence (NICE) end-of-life guidance rule’ can be useful for drugs struggling to gain a positive NICE opinion. By targeting terminal patients with months to live, they can achieve market access and a route into the treatment of other stages of a disease, but only if further concessions are made to reduce the drug's quality-adjusted life year (QALY).
They further note that if a Health Technology Assessment (HTA) is introduced in the US, it could create a more cost-effective use of current US healthcare resources, however it is important to note this will increase the burden on Pharma to produce data, and could also effectively lead to the end of free pricing in the US.
The report provides:
* Overview of the different types of risk-sharing agreements adopted by manufacturers
* Insight into the utilisation of such schemes in the UK, US, Italy and Australia
* Identification of key strategic recommendations for optimising risk-sharing strategies
“Pricing and Reimbursement:
http://www.piribo.com/
Piribo product ID: DAT01768
